Breast cancer genomics and immuno-oncological markers to guide immune therapies. (October 2018)

• Record Type: Journal Article
• Authors: Hammerl, D.; Smid, M.; Timmermans, A.M.; Sleijfer, S.; Martens, J.W.M.; Debets, R.
• Is Part Of: Seminars in cancer biology. Volume 52(2018)Part 2
• Page Start: 178
• Page End: 188
• Publication Date: 2018-10
• Subjects: APC antigen presenting cell -- APOBEC apolipoprotein B mRNA editing enzyme catalytic polypeptide-like -- BRCA1/2 breast cancer 1/2 -- BCSS breast cancer specific survival -- B2M β-2-microglobulin -- CAF cancer associated fibroblast -- CCL chemokine ligand -- CD cluster of differentiation -- CMV cytomegalo virus -- CTLA4 cytotoxic T lymphocyte associated protein 4 -- CR Complete response -- CXCL CXC-motif chemokine ligand -- DC dendritic cell -- DCIS ductal carcinoma in situ -- DFS disease free survival -- EBV epstein-barr virus -- ECM extracellular matrix -- ELF5 E75 like ETS transcription factor 5 -- EMT epithelial − mesenchymal transition -- GBP1 interferone induced guanylate binding protein 1 -- GRZM granzyme -- H&E hematoxylin and eosin -- HER2 human epidermal growth factor receptor 2 -- HERV-K human endogenous retrovirus K -- HLA human leucocyte antigen -- HPV human papiloma virus -- HR hormone receptor or hazard ratio -- hTERT telomerase reverse transcriptase -- IDC invasive ductal carcinoma -- IDO1 indoleamine-pyrrole 2, 3-dioxygenase -- IFN interferon -- IGK immunoglobin kappa locus -- IGLL5 immunoglobin lambda like polypeptide 5 -- JAK1/2 Janus kinase 1/2 -- LAG3 lymphocyte activation gene 3 -- MDSC myeloid derived suppressor cell -- MEK map kinase kinase -- MFS metastasis free survival -- MHC major histocompatibility complex -- MMTV mouse mammary tumor virus -- MUC1 mucin 1 -- MV measles virus -- NK natural killer cell -- NO nitric oxide -- OCLN occludin -- OR objective response or odds ratio -- OS overall survival -- PC plasma cell -- PD1 programmed cell death protein 1 -- PDL1 programmed death ligand -- PI3K phosphoinositol 3-kinase -- PR progesteron receptor -- PTEN phosphatase and tensin homolog -- RFS relapse-free survival -- ROS reactive oxygen species -- SD stable disease -- STAT1 signal transducer and activator of transcription 1 -- TAA tumor associated antigen -- TAP transport associated protein -- TIL tumor infiltrating leukocytes -- TLS tertiary lymphoid structures -- TGFB transforming growth factor beta -- TNBC triple negative breast cancer -- TNFa tumor necrosis factor alpha -- Treg Regulatory T cell -- Tγδ gamma delta T cell; Breast cancer -- Immunotherapy -- TILs -- Antigens -- Immune evasive mechanisms -- Immune-oncological markers; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2017.11.003
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: There is an increasing awareness of the importance of tumor – immune cell interactions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, numerous studies are currently assessing the clinical value of immune modulation for BC patients. However, till now durable clinical responses are only rarely observed. It is important to realize that BC is a heterogeneous disease comprising several histological and molecular subtypes, which cannot be expected to be equally immunogenic and therefore not equally sensitive to single immune therapies. Here we review the characteristics of infiltrating leukocytes in healthy and malignant breast tissue, the prognostic and predictive values of immune cell subsets across different BC subtypes and the various existing immune evasive mechanisms. Furthermore, we describe the presence of certain groups of antigens as putative targets for treatment, evaluate the outcomes of current clinical immunotherapy trials, and finally, we propose a strategy to better implement immuno-oncological markers to guide future immune therapies in BC.